Angiosil retard, 35 mg 60 pcs

Anguisil retard has antianginal, antihypoxic action. Angiosyl retard has a direct effect on cardiomyocytes and neurons of the brain and optimizes their metabolism and function. Cytoprotective effect is due to increase of energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increase of aerobic glycolysis and blockade of fatty acid oxidation). It supports myocardial contractility and prevents the decrease of intracellular ATP and phosphocreatinine.

Indications

– chorioretinal vascular disorders;
– CHD: prevention of angina attacks (as part of complex therapy);
– dizziness of vascular origin;
– cochleo-vestibular disorders of ischemic nature (tinnitus, hearing loss).

Active ingredient

Composition

1 tablet contains trimetazidine dihydrochloride 35 mg.

How to take, the dosage

Anguisil retard is prescribed at 35 mg (1 tablet) 2 times a day. Tablets are taken orally with meals in the morning and in the evening. The duration of therapy with Angiozil Retard is determined individually.

Interaction

Interaction with other drugs has not been described.

Special Instructions

Angiosyl retard is not intended to stop angina attacks. In case of angina attacks, treatment should be corrected. Angiosyl retard does not affect the ability to engage in potentially hazardous activities requiring increased attention and high speed of psychomotor reactions.

Contraindications

– hypersensitivity to the drug components
– renal insufficiency (CK – marked liver dysfunction;
– pregnancy;
– lactation (breast-feeding) period;
– children and adolescents under 18 years of age (effectiveness and safety of the drug are not established)

Side effects

The digestive system: rarely – gastralgia, nausea, vomiting.
Allergic reactions: skin itching.
Other: rarely – headache, feeling of palpitations.

Overdose

There are currently no reported cases of overdose of Angiosil Retard.

Similarities